DC Circ. Won't Revisit Takeda's Gout Drug Dispute With FDA
The D.C. Circuit on Thursday said it wouldn't reconsider its dismissal of Takeda Pharmaceuticals USA Inc.'s suit accusing the U.S. Food and Drug Administration of violating patent protections by approving West-Ward...To view the full article, register now.
Already a subscriber? Click here to view full article